Cancer Check Labs

Cancer Check Labs offers a blood-based multi-cancer early detection test that screens for more than 200 types and subtypes of solid tumor cancers. The test works by physically extracting whole, intact circulating tumor cells from a blood sample, which are then visually inspected by a board-certified pathologist. Because circulating tumor cells can be detected as early as Stage 0, when survival rates reach 99%, the company positions this as among the earliest cancer detection methods available today.

Unlike traditional cancer screenings that target specific cancer types, Cancer Check provides a pan-cancer approach from a single blood draw. This addresses a significant gap in current screening: many cancers including pancreatic, stomach, bladder, kidney, liver, and brain cancers lack available screenings, making early detection difficult. The test is available across all 48 continental US states and select areas of Canada, with results delivered through a comprehensive pathology report.

The company's clinical laboratory holds federal certification under the Clinical Laboratory Improvement Amendments of 1988 and is regulated by the Centers for Medicare and Medicaid Services. Cancer Check Labs emphasizes that the test is not intended to replace established evidence-based screening guidelines and acknowledges limitations inherent to all medical tests.